Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis

Objective Erythropoiesis‐stimulating agents (ESAs) are commonly used to treat the anemia of myelofibrosis (MF), but information on the predictors of response is limited. Methods Results of ESA therapy were analyzed in 163 MF patients with severe anemia, most of whom had inadequate erythropoietin (EP...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2017-04, Vol.98 (4), p.407-414
Main Authors: Hernández‐Boluda, Juan‐Carlos, Correa, Juan‐Gonzalo, García‐Delgado, Regina, Martínez‐López, Joaquín, Alvarez‐Larrán, Alberto, Fox, María‐Laura, García‐Gutiérrez, Valentín, Pérez‐Encinas, Manuel, Ferrer‐Marín, Francisca, Mata‐Vázquez, María‐Isabel, Raya, José‐María, Estrada, Natalia, García, Silvia, Kerguelen, Ana, Durán, María‐Antonia, Albors, Manuel, Cervantes, Francisco
Format: Article
Language:English
Subjects:
Aged
Anemia
Anemia - blood
Anemia - drug therapy
Anemia - mortality
Disease-Free Survival
Erythropoiesis
erythropoiesis‐stimulating agents
Erythropoietin
Erythropoietin - blood
Female
Ferritin
Ferritins - blood
Hematinics - administration & dosage
Hematinics - adverse effects
Humans
Leukocyte Count
Male
Middle Aged
Multivariate analysis
Myelofibrosis
Patients
predictive factors
Primary Myelofibrosis - blood
Primary Myelofibrosis - drug therapy
Primary Myelofibrosis - mortality
Response rates
Sex Factors
Spain - epidemiology
Survival Rate
Thrombosis - blood
Thrombosis - chemically induced
Thrombosis - mortality
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Erythropoiesis‐stimulating agents (ESAs) are commonly used to treat the anemia of myelofibrosis (MF), but information on the predictors of response is limited. Methods Results of ESA therapy were analyzed in 163 MF patients with severe anemia, most of whom had inadequate erythropoietin (EPO) levels (
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.12846